CR20220288A - Anticuerpos contra integrina alfa 11 beta 1 - Google Patents

Anticuerpos contra integrina alfa 11 beta 1

Info

Publication number
CR20220288A
CR20220288A CR20220288A CR20220288A CR20220288A CR 20220288 A CR20220288 A CR 20220288A CR 20220288 A CR20220288 A CR 20220288A CR 20220288 A CR20220288 A CR 20220288A CR 20220288 A CR20220288 A CR 20220288A
Authority
CR
Costa Rica
Prior art keywords
beta
integrin alpha
antibodies against
antibodies
against integrin
Prior art date
Application number
CR20220288A
Other languages
English (en)
Inventor
James W Meador Iii
Elma Kurtagic
Christopher Beneduce
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CR20220288A publication Critical patent/CR20220288A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

<strong> </strong>La presente divulgación incluye anticuerpos que se unen específicamente a la integrina alfa 11 beta 1 (α11β1), así como métodos de fabricación y uso de dichos anticuerpos.
CR20220288A 2019-12-20 2020-12-18 Anticuerpos contra integrina alfa 11 beta 1 CR20220288A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
CR20220288A true CR20220288A (es) 2022-10-07

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220288A CR20220288A (es) 2019-12-20 2020-12-18 Anticuerpos contra integrina alfa 11 beta 1

Country Status (17)

Country Link
US (1) US20230050972A1 (es)
EP (1) EP4076525A4 (es)
JP (1) JP2023508286A (es)
KR (1) KR20220123013A (es)
CN (1) CN115135342A (es)
AU (1) AU2020407124A1 (es)
BR (1) BR112022012093A2 (es)
CA (1) CA3165386A1 (es)
CL (1) CL2022001673A1 (es)
CO (1) CO2022010204A2 (es)
CR (1) CR20220288A (es)
DO (1) DOP2022000129A (es)
EC (1) ECSP22056627A (es)
IL (1) IL294047A (es)
MX (1) MX2022007521A (es)
PE (1) PE20221723A1 (es)
WO (1) WO2021127500A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303741A (en) * 2020-12-18 2023-08-01 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 in cell 1
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2023250415A2 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
EP2101818A1 (en) * 2006-12-18 2009-09-23 Cartela R&D AB Binding agents to the integrin alpha-11 subunit, and uses thereof
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
US20230065153A1 (en) * 2018-03-01 2023-03-02 Hiroshima University Anti-integrin alpha-11 monoclonal antibody and use thereof

Also Published As

Publication number Publication date
DOP2022000129A (es) 2022-10-31
EP4076525A1 (en) 2022-10-26
US20230050972A1 (en) 2023-02-16
KR20220123013A (ko) 2022-09-05
CL2022001673A1 (es) 2023-02-03
IL294047A (en) 2022-08-01
MX2022007521A (es) 2022-07-19
AU2020407124A1 (en) 2022-07-21
WO2021127500A9 (en) 2021-07-29
JP2023508286A (ja) 2023-03-02
CA3165386A1 (en) 2021-06-24
WO2021127500A1 (en) 2021-06-24
BR112022012093A2 (pt) 2022-08-30
ECSP22056627A (es) 2022-11-30
EP4076525A4 (en) 2024-05-01
CN115135342A (zh) 2022-09-30
PE20221723A1 (es) 2022-11-04
CO2022010204A2 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
CR20220288A (es) Anticuerpos contra integrina alfa 11 beta 1
PH12019502459A1 (en) Anti-trem2 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
CR20190486A (es) Anti-cd33 antibodies and methods of use thereof
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
ZA202008095B (en) Humanized antibodies against psma
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
MX2022007156A (es) Metodos de uso de anticuerpos anti-cd33.
MX2022003159A (es) Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.